Literature DB >> 14975587

Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate.

Stefan Jung1, Ines Siglienti, Oliver Grauer, Tim Magnus, Guglielmo Scarlato, Klaus Toyka.   

Abstract

Glatiramer acetate (GLAT) is a mixture of basic polypeptides that have been shown to suppress experimental autoimmune encephalomyelitis (EAE). As Copaxone, GLAT is approved for the treatment of relapsing-remitting multiple sclerosis (MS). Different immunomechanisms have been suggested to contribute to the beneficial effects of GLAT which rely on blockade of MHC class II molecules or cross-recognition with myelin basic protein (MBP). Because GLAT could also inhibit experimental autoimmunity not related to myelin proteins, we searched for additional, less-restricted immunomodulatory actions of GLAT. Using freshly isolated resident peritoneal macrophages from naive Lewis rats, it is shown that GLAT profoundly modulates cytokine secretion of the cells. In unseparated macrophages (MPhi) and MPhi of low density, GLAT enhanced constitutive and LPS-induced production of interleukin 10 (IL-10) while LPS-induced synthesis of tumor necrosis factor-alpha (TNF-alpha) was dose-dependently suppressed by GLAT. Although both basic proteins GLAT and MBP facilitated adherence of MPhi, MBP had opposite effects on cytokine production suggesting unique properties of GLAT. In contrast to MPhi, peritoneal mast cells produced only little amounts of cytokines. The inductive effect of GLAT on IL-10 production by antigen-presenting cells was also observed in bone marrow-derived rat dendritic cells (DCs) which, unlike MPhi, were not suppressed in their production of TNF-alpha. Induction of IL-10 in different antigen-presenting cells is a new immunomodulatory mechanism of GLAT. In part, it goes along with the inhibition of TNF-alpha and may be a common basis for the known beneficial effects of GLAT on various cellular autoimmune responses including MS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14975587     DOI: 10.1016/j.jneuroim.2003.11.014

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  23 in total

Review 1.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

2.  Glatiramer acetate triggers PI3Kδ/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes.

Authors:  Rakel Carpintero; Karim J Brandt; Lyssia Gruaz; Nicolas Molnarfi; Patrice H Lalive; Danielle Burger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

3.  Glatiramer acetate modulates TNF-α and IL-10 secretion in microglia and promotes their phagocytic activity.

Authors:  Refik Pul; Darius Moharregh-Khiabani; Jelena Škuljec; Thomas Skripuletz; Niklas Garde; Elke Verena Voss; Martin Stangel
Journal:  J Neuroimmune Pharmacol       Date:  2010-11-03       Impact factor: 4.147

4.  Fasudil regulates T cell responses through polarization of BV-2 cells in mice experimental autoimmune encephalomyelitis.

Authors:  Chan Chen; Yan-hua Li; Qiong Zhang; Jie-zhong Yu; Yong-fei Zhao; Cun-gen Ma; Bao-guo Xiao
Journal:  Acta Pharmacol Sin       Date:  2014-09-29       Impact factor: 6.150

Review 5.  Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

Review 6.  The Evolving Mechanisms of Action of Glatiramer Acetate.

Authors:  Thomas Prod'homme; Scott S Zamvil
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

Review 7.  Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.

Authors:  Martin S Weber; Reinhard Hohlfeld; Scott S Zamvil
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

8.  Immunophototherapy using PDT combined with rapid intratumoral dendritic cell injection.

Authors:  Brandon W Sur; Phuong Nguyen; Chung-Ho Sun; Bruce J Tromberg; Edward L Nelson
Journal:  Photochem Photobiol       Date:  2008-04-23       Impact factor: 3.421

9.  Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy.

Authors:  Evan Sloane; A Ledeboer; W Seibert; B Coats; M van Strien; S F Maier; K W Johnson; R Chavez; L R Watkins; L Leinwand; E D Milligan; A M Van Dam
Journal:  Brain Behav Immun       Date:  2008-09-20       Impact factor: 7.217

10.  Increase of Alternatively Activated Antigen Presenting Cells in Active Experimental Autoimmune Encephalomyelitis.

Authors:  Beatrice Wasser; Gautam Pramanik; Moritz Hess; Matthias Klein; Felix Luessi; Klaus Dornmair; Tobias Bopp; Frauke Zipp; Esther Witsch
Journal:  J Neuroimmune Pharmacol       Date:  2016-07-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.